openPR Logo
Press release

Metastatic Melanoma Cancer Diagnostics Market is estimated to be valued at US$ 2.9 Bn at a CAGR of close to 8% in 2022

06-22-2022 08:14 PM CET | Health & Medicine

Press release from: Persistence Market Research

/ PR Agency: Persistence Market Research
Metastatic Melanoma Cancer Diagnostics Market 2022

Metastatic Melanoma Cancer Diagnostics Market 2022

Metastatic Melanoma Cancer Diagnostics Market 2022

The global metastatic melanoma cancer diagnostics market is estimated to be valued at US$ 2.9 Bn in 2022, and exhibit a CAGR of close to 8% over the forecast period (2021 - 2031).

Free Sample Copy of This Report@https://www.persistencemarketresearch.com/samples/32446

Rising prevalence of metastatic melanoma cancer has been witnessed over the years. Verified therapeutics and diagnostics have a positive impact on treating the disease and extending the life span of patients. Improving sophistication in healthcare facilities and technological developments across the world are key factors expanding the market for metastatic melanoma cancer diagnostics. Government initiatives related to creating awareness for early diagnosis and treatment are also expected to drive demand for metastatic melanoma cancer diagnostics.

Key Takeaways from Market Study

PET scan test holds the highest value share in market under products, owing to advantages such as it shortens test time and provides accurate attenuation correction and fusion imaging, leading to an increase in diagnostic sensitivity and specificity.

By service provider, pathology laboratories hold a notable revenue share of more than half in the market.

Owing to rising cancer cases and increased awareness about cancer screening, the pathology laboratories segment is expected to experience lucrative growth among all service providers at a CAGR of 8.5% through 2031.

North America accounted for a share of more than 45% in 2020. It is the most lucrative market among all regions and is expected to experience significant growth over the next ten years.
Europe is the next dominating region with a market share of 35% in 2020, due to the flourishing cancer diagnostics industry in the region.

"Rising prevalence of metastatic melanoma disorders, increasing demand for non-invasive diagnostic therapy, and developments in metastatic melanoma cancer are is expected to drive market growth," says a Persistence Market Research analyst.

Request For Customization@https://www.persistencemarketresearch.com/request-customization/32446

COVID-19 Impact

According to the American Society of Clinical Oncology, the COVID-19 disease has tremendously disrupted healthcare facilities, globally. COVID-19 has also led to disruption in cancer services. The pandemic has resulted in heavy reduction in diagnosis, non-elective surgeries, and non-essential medical visits. Delay in visits for diagnosis can lead to delay in treatment for melanoma and other skin cancers, leading to serious health issues. All in all, the market witnessed sluggish growth due to the onset of the COVID-19 outbreak. However, as things have opened up, the market is set to recover some of its lost pace over the coming months and years.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the metastatic melanoma cancer diagnostics market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021-2031, based on product (biopsy, chest X-ray, lymphoscintigraphy, ultrasound, CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, and PET (positron emission tomography) scans)) and service provider (hospitals, pathology laboratories, and cancer research centers), across seven key regions of the world.

Get Full Report Now@https://www.persistencemarketresearch.com/checkout/32446

Persistence Market Research's Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations.

Access Related Reports:

Holter Monitoring Systems Market -https://www.persistencemarketresearch.com/market-research/holter-monitoring-systems-market.asp

Global Holter Monitoring Systems Market revenue & valuation from the market in the region is expected to expand at CAGR of 5.2% over the forecast period.

Wireless Fetal Monitoring Systems Market -https://www.persistencemarketresearch.com/market-research/wireless-fetal-monitoring-systems-market.asp

The global wireless fetal monitoring system estimated to be worth US$ 1,242.2 Mn by 2018 end and is expected to expand at a CAGR of 6.8% over the forecast period of 2018-2026.

Media Contact:

Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About PersistenceMarketResearch:

PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic Melanoma Cancer Diagnostics Market is estimated to be valued at US$ 2.9 Bn at a CAGR of close to 8% in 2022 here

News-ID: 2659761 • Views:

More Releases from Persistence Market Research

Antimicrobial Additives Market Expected to Grow at 7.8% CAGR Between 2025 and 2032 - Persistence Market Research
Antimicrobial Additives Market Expected to Grow at 7.8% CAGR Between 2025 and 20 …
The antimicrobial additives market has evolved into a critical segment within the global specialty chemicals and materials landscape, driven by the growing need to control microbial contamination across healthcare, food packaging, construction, automotive, and consumer goods industries. Antimicrobial additives are incorporated into materials such as plastics, coatings, textiles, and papers to inhibit the growth of bacteria, fungi, and other microorganisms throughout a product's lifecycle. Their role has expanded beyond basic
Smart Manufacturing Market Valued at US$394.4 Billion in 2025, Expected to Reach US$999.0 Billion by 2032 | Persistence Market Research
Smart Manufacturing Market Valued at US$394.4 Billion in 2025, Expected to Reach …
The smart manufacturing market represents a fundamental transformation in how goods are designed, produced, monitored, and delivered across global industries. It combines advanced digital technologies such as industrial Internet of Things (IIoT), artificial intelligence (AI), machine learning, robotics, cloud computing, digital twins, and advanced analytics to create highly connected, automated, and intelligent production environments. Unlike traditional manufacturing, smart manufacturing enables real-time decision-making, predictive maintenance, adaptive production planning, and end-to-end visibility
Oligonucleotide Synthesis Market Forecast Signals Strong Expansion During 2025-2032 | Persistence Market Research
Oligonucleotide Synthesis Market Forecast Signals Strong Expansion During 2025-2 …
The oligonucleotide synthesis market has evolved from a niche research-support function into a strategic pillar of modern biotechnology and pharmaceutical development. Oligonucleotides-short, synthetically produced DNA or RNA sequences-are indispensable in applications ranging from basic genetic research and molecular diagnostics to advanced therapeutics such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and RNA- and DNA-based vaccines. As precision medicine continues to reshape healthcare, the ability to reliably synthesize high-quality, customized
Genome Editing Market Demand Surges Across Biotechnology and Pharmaceutical Sectors - Persistence Market Research
Genome Editing Market Demand Surges Across Biotechnology and Pharmaceutical Sect …
The genome editing market has emerged as one of the most transformative segments within modern biotechnology, reshaping how scientists, clinicians, and agricultural innovators approach genetic modification. Genome editing refers to a suite of technologies that allow precise alterations to DNA within living organisms, enabling the correction of genetic defects, enhancement of desirable traits, and development of advanced therapeutic solutions. Over the past decade, breakthroughs such as CRISPR/Cas9, base editing, and

All 5 Releases


More Releases for Metastatic

Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025? The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034? The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market? The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth? The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size? The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer. Download Report: https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control